MARKET

SPRB

SPRB

SPRUCE BIOSCIENCES, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.90
-0.31
-1.46%
After Hours: 20.90 0 0.00% 16:00 02/26 EST
OPEN
21.20
PREV CLOSE
21.21
HIGH
22.35
LOW
20.90
VOLUME
40.58K
TURNOVER
--
52 WEEK HIGH
35.60
52 WEEK LOW
15.12
MARKET CAP
444.41M
P/E (TTM)
-26.8224
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Spruce Biosciences to Participate in Upcoming Investor Conferences
Spruce Biosciences to Participate in Upcoming Investor Conferences
Business Wire · 02/17 21:05
What Type Of Shareholders Make Up Spruce Biosciences, Inc.'s (NASDAQ:SPRB) Share Registry?
A look at the shareholders of Spruce Biosciences, Inc. ( NASDAQ:SPRB ) can tell us which group is most powerful...
Simply Wall St. · 01/12 10:10
What Type Of Shareholders Make Up Spruce Biosciences, Inc.'s (NASDAQ:SPRB) Share Registry?
A look at the shareholders of Spruce Biosciences, Inc. ( NASDAQ:SPRB ) can tell us which group is most powerful...
Simply Wall St. · 01/12 10:10
What Type Of Shareholders Make Up Spruce Biosciences, Inc.'s (NASDAQ:SPRB) Share Registry?
A look at the shareholders of Spruce Biosciences, Inc. ( NASDAQ:SPRB ) can tell us which group is most powerful...
Simply Wall St. · 01/12 10:10
Spruce Biosciences outlines milestones for 2021
Spruce Biosciences (SPRB) provides corporate update and outlines milestones for 2021:Initiate Phase 2 program for its CRF1 receptor antagonist tildacerfont for the treatment of classic classic congenital adrenal hyperplasia ((CAH)) in children
Seekingalpha · 01/06 17:41
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
Business Wire · 01/06 13:00
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
Business Wire · 01/06 13:00
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
Business Wire · 01/06 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPRB. Analyze the recent business situations of SPRUCE BIOSCIENCES, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SPRB stock price target is 33.75 with a high estimate of 44.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 44
Institutional Holdings: 16.73M
% Owned: 78.68%
Shares Outstanding: 21.26M
TypeInstitutionsShares
Increased
0
0
New
44
16.73M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Michael Grey
Chief Executive Officer/Director/Primary Contact
Richard King
Vice President
Chris Barnes
Other
Michael Huang
Director
Niall O Donnell
Director
Niall O'donnell
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal, oral antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is the receptor for corticotropin-releasing factor (CRF). By blocking the CRF1 receptor, tildacerfont enables to address the uncontrolled cortisol feedback regulatory pathway in CAH and reduce the production of adrenocorticotropic hormone (ACTH) in the pituitary, limiting the amount of androgen produced downstream from the adrenal gland. Tildacerfont also enables treating physicians to lower the supraphysiologic glucocorticoid doses given to CAH patients to near physiologic levels.

Webull offers kinds of Spruce Biosciences Inc stock information, including NASDAQ:SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.